542 related articles for article (PubMed ID: 15121300)
1. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model.
David S; van Furth R; Mooi FR
Vaccine; 2004 May; 22(15-16):1892-8. PubMed ID: 15121300
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
[TBL] [Abstract][Full Text] [Related]
3. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.
Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D
Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570
[TBL] [Abstract][Full Text] [Related]
4. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
Denoël P; Godfroid F; Guiso N; Hallander H; Poolman J
Vaccine; 2005 Nov; 23(46-47):5333-41. PubMed ID: 16054273
[TBL] [Abstract][Full Text] [Related]
5. Bordetella parapertussis infections.
Mastrantonio P; Giuliano M; Stefanelli P; Sofia T; De Marzi L; Tarabini G; Quarto M; Moiraghi A
Dev Biol Stand; 1997; 89():255-9. PubMed ID: 9272358
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the whole-cell pertussis vaccine produced in Poland against different Bordetella parapertussis isolates in the mouse intranasal challenge model.
Zawadka M; Polak M; Rabczenko D; Mosiej E; Augustynowicz E; Lutyńska A
Vaccine; 2011 Jul; 29(33):5488-94. PubMed ID: 21641954
[TBL] [Abstract][Full Text] [Related]
7. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children.
Mahon BP; Brady MT; Mills KH
J Infect Dis; 2000 Jun; 181(6):2087-91. PubMed ID: 10837200
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model.
Willems RJ; Kamerbeek J; Geuijen CA; Top J; Gielen H; Gaastra W; Mooi FR
Vaccine; 1998 Feb; 16(4):410-6. PubMed ID: 9607064
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.
Watanabe M; Nagai M
Infect Immun; 2001 Nov; 69(11):6981-6. PubMed ID: 11598073
[TBL] [Abstract][Full Text] [Related]
10. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
[TBL] [Abstract][Full Text] [Related]
11. A recombinant iron transport protein from Bordetella pertussis confers protection against Bordetella parapertussis.
Alvarez Hayes J; Oviedo JM; Valdez H; Laborde JM; Maschi F; Ayala M; Shah R; Fernandez Lahore M; Rodriguez ME
Microbiol Immunol; 2017 Oct; 61(10):407-415. PubMed ID: 28857261
[TBL] [Abstract][Full Text] [Related]
12. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
Heininger U; Stehr K; Christenson P; Cherry JD
Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
[TBL] [Abstract][Full Text] [Related]
13. Serological responses to infection with B. pertussis.
Giammanco A; Taormina S; Genovese M; Mangiaracina G; Giammanco G; Chiarini A
Dev Biol Stand; 1997; 89():213-20. PubMed ID: 9272353
[TBL] [Abstract][Full Text] [Related]
14. A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity.
Mills KH; Brady M; Ryan E; Mahon BP
Dev Biol Stand; 1998; 95():31-41. PubMed ID: 9855412
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
[TBL] [Abstract][Full Text] [Related]
17. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
[TBL] [Abstract][Full Text] [Related]
18. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
Tapiainen T; Cherry JD; Heininger U
Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
[TBL] [Abstract][Full Text] [Related]
19. [Acellular pertussis vaccine].
Wiedermann G; Ambrosch F; Vanura H
Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
[TBL] [Abstract][Full Text] [Related]
20. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy.
Dirix V; Verscheure V; Goetghebuer T; Hainaut M; Debrie AS; Locht C; Mascart F
Vaccine; 2009 Oct; 27(43):6042-7. PubMed ID: 19665604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
